Greg Yap

Menlo Ventures

Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo’s investments in Clear Labs, Delfi Diagnostics, Encoded Therapeutics, Epiodyne, Genesis Therapeutics, H1 Insights, Ophelia Health, Particle Health, Pliant Therapeutics (NASDAQ: PLRX), Senti Biosciences, Scribe Therapeutics and Riva Health. He has also been involved in investments in Benchling, Recursion Pharmaceuticals, and Cofactor Ge

HLTH does not sell or provide any personal data (including email, phone, address) to any third parties and we never will. Any communication that pretends to be HLTH or any third parties selling purported lists, discounted rooms, or any product/services are NOT AFFILIATED with HLTH and are to be considered FRAUD.

Upcoming Event Dates

2024 | ViVE: Feb 25-28; HLTH Europe: Jun 17-20; HLTH US: Oct 20-23

2025 | ViVE: Feb 16-19; HLTH US: Oct 19-22

2026 | HLTH US: Nov 15-18

2027 | HLTH US: Oct 17-20

© 2024 HLTH, INC. All Rights Reserved